Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,054 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Colon Clear all
Completed No phase listed Observational

Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients

NCT02186236
View directory record Official record
Conditions
Lung Cancer, Colorectal Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • East White Plains, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

NCT03667716
View directory record Official record
Conditions
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer
Interventions
COM701, COM701 with Opdivo (Nivolumab).
Drug
Lead sponsor
Compugen Ltd
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Sarasota, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

NCT00033306
View directory record Official record
Conditions
Colorectal Cancer
Interventions
ixabepilone, Fluoropyrimidine, Irinotecan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 1 Interventional Results available

Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

NCT02972034
View directory record Official record
Conditions
Neoplasms, Colorectal Cancer
Interventions
MK-8353, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Grand Rapids, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

NCT00574171
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
lapatinib, Capecitabine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions
MRTX1133
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 25, 2026, 8:16 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT05710406
View directory record Official record
Conditions
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Encorafenib, Cetuximab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Patient Observation
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
202
States / cities
Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 159 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 25, 2026, 8:16 AM EDT
Withdrawn No phase listed Observational

Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

NCT01012804
View directory record Official record
Conditions
Colorectal Cancer
Interventions
western blotting, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening

NCT04585919
View directory record Official record
Conditions
Colorectal Cancer, Social Determinants of Health
Interventions
Paired Screening Intervention
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Brockton, Massachusetts • Lowell, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 25, 2026, 8:16 AM EDT
Active, not recruiting Phase 1 Interventional

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030
View directory record Official record
Conditions
Colorectal Cancer
Interventions
M9140, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Encinitas, California • Fresno, California • Providence, Rhode Island + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 8:16 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT01447199
View directory record Official record
Conditions
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Skin Cancer, Uterus Cancer
Interventions
Health and Diet Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Not applicable Interventional

Geographically Clustered Mailing of Fecal Immunochemical Test (FIT) Kits

NCT03718221
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Usual Care FIT Screening Strategy, GeoMail FIT Screening Strategy
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 64 Years
Enrollment
8,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer

NCT00331786
View directory record Official record
Conditions
Colorectal Cancer
Interventions
nitric oxide-releasing acetylsalicylic acid derivative, laboratory biomarker analysis, biopsy
Drug · Other · Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 25, 2026, 8:16 AM EDT
Active, not recruiting Not applicable Interventional Results available

ASPirin Intervention for the REDuction of Colorectal Cancer Risk

NCT02394769
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Aspirin, Placebo for Aspirin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

NCT01545141
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 25, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Unprepped CT Colonography

NCT00586053
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
1,255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 1 Interventional

Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver

NCT02110953
View directory record Official record
Conditions
Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan-eluting beads, hepatic artery embolization
Combination Product · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated No phase listed Observational

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

NCT02503631
View directory record Official record
Conditions
Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions
Stool Sample Collection Kit
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years to 90 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Newport Beach, California • Hamden, Connecticut • Holiday, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

NCT00648102
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
Interventions
CDX-1307
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Oct 25, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-930
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 25, 2026, 8:16 AM EDT
Active, not recruiting Phase 2 Interventional

Acupuncture Pilot Study for Cancer-related Cognitive Function

NCT04007770
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer, Gynecologic Cancer, Stage I Gynecologic Cancer, Stage II Gynecologic Cancer, Stage III Gynecologic Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 8:16 AM EDT
Active, not recruiting Early Phase 1 Interventional

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

NCT03164486
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma
Interventions
18F-αvβ6-BP
Drug
Lead sponsor
Julie L. Sutcliffe, Ph.D
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 8:16 AM EDT
Terminated Phase 2 Interventional

Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases

NCT00106054
View directory record Official record
Conditions
Colorectal Neoplasms, Liver Neoplasms
Interventions
Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 25, 2026, 8:16 AM EDT